AlphaCentric Advisors LLC Cuts Stake in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM)

AlphaCentric Advisors LLC cut its holdings in shares of Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) by 29.7% in the 3rd quarter, Holdings Channel reports. The fund owned 45,000 shares of the company’s stock after selling 19,000 shares during the period. Mirum Pharmaceuticals accounts for about 1.3% of AlphaCentric Advisors LLC’s investment portfolio, making the stock its 23rd biggest position. AlphaCentric Advisors LLC’s holdings in Mirum Pharmaceuticals were worth $1,755,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the business. Janus Henderson Group PLC grew its stake in shares of Mirum Pharmaceuticals by 34.2% during the first quarter. Janus Henderson Group PLC now owns 2,767,210 shares of the company’s stock valued at $69,470,000 after acquiring an additional 704,659 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in shares of Mirum Pharmaceuticals by 37.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 1,597,506 shares of the company’s stock valued at $40,131,000 after acquiring an additional 432,824 shares in the last quarter. Clearbridge Investments LLC grew its stake in shares of Mirum Pharmaceuticals by 165.5% during the second quarter. Clearbridge Investments LLC now owns 699,933 shares of the company’s stock valued at $23,931,000 after acquiring an additional 436,349 shares in the last quarter. William Blair Investment Management LLC grew its stake in shares of Mirum Pharmaceuticals by 8.1% during the second quarter. William Blair Investment Management LLC now owns 677,939 shares of the company’s stock valued at $23,179,000 after acquiring an additional 50,667 shares in the last quarter. Finally, Candriam S.C.A. acquired a new stake in shares of Mirum Pharmaceuticals during the second quarter valued at about $17,384,000.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on MIRM shares. Robert W. Baird raised their target price on Mirum Pharmaceuticals from $39.00 to $44.00 and gave the company an “outperform” rating in a research note on Thursday, August 8th. Cantor Fitzgerald lifted their price target on Mirum Pharmaceuticals from $50.00 to $60.00 and gave the stock an “overweight” rating in a research note on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and issued a $66.00 price target on shares of Mirum Pharmaceuticals in a research note on Friday, October 11th. Evercore ISI lifted their price target on Mirum Pharmaceuticals from $62.00 to $66.00 and gave the stock an “outperform” rating in a research note on Thursday, August 8th. Finally, Leerink Partners lifted their price target on Mirum Pharmaceuticals from $47.00 to $49.00 and gave the stock an “outperform” rating in a research note on Thursday, October 17th. Ten equities research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock currently has an average rating of “Buy” and an average price target of $56.82.

Mirum Pharmaceuticals Stock Up 0.1 %

Shares of MIRM stock opened at $40.45 on Tuesday. The company has a debt-to-equity ratio of 1.34, a quick ratio of 3.09 and a current ratio of 3.28. The business has a 50 day moving average of $40.10 and a two-hundred day moving average of $35.00. Mirum Pharmaceuticals, Inc. has a 52 week low of $23.14 and a 52 week high of $45.23.

Mirum Pharmaceuticals (NASDAQ:MIRM) last issued its earnings results on Wednesday, August 7th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.05). Mirum Pharmaceuticals had a negative net margin of 40.34% and a negative return on equity of 43.47%. The company had revenue of $77.90 million during the quarter, compared to analyst estimates of $75.03 million. During the same quarter in the previous year, the firm earned ($0.92) earnings per share. The business’s revenue was up 107.7% on a year-over-year basis. As a group, equities analysts predict that Mirum Pharmaceuticals, Inc. will post -1.84 earnings per share for the current fiscal year.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally.